At Week 52 (SINUS-52), DUPIXENT demonstrated1:

-1.34
IMPROVEMENT
IN NC SCORE

LSM change from a baseline
score of 2.38 (n=35)

vs

-0.21 improvement from a
baseline score of 2.49 with
placebo + INCS (n=44) (LSM
difference vs placebo: -1.13
[95% CI: -1.49, -0.77])1

-2.54
IMPROVEMENT
IN NPS

LSM change from a baseline
score of 5.87 (n=35)

vs

0.03 worsening with
placebo + INCS (n=44) (LSM
change from a baseline
score of 6.06) (LSM
difference vs placebo: -2.57
[95% CI: -3.27, -1.87])1

-7.27
IMPROVEMENT
IN LMK-CT SCORE

LSM change from a baseline
score of 19.71 (n=35)

vs

-0.41 improvement from a
baseline score of 19.07 with
placebo + INCS (n=44) (LSM
difference vs placebo: -6.86
[95% CI: -8.62, -5.10])1

Analysis was not multiplicity controlled; results are descriptive.


27% of patients enrolled in SINUS-52 presented with NSAID-ERD.2

INCS, intranasal corticosteroid; LSM, least squares mean; NC, nasal congestion/obstruction; NPS, nasal polyp score; NSAID-ERD, nonsteroidal anti-inflammatory drug–exacerbated respiratory disease.

SEE SAFETY DATA
Back to snot-22 results

Explore the Safety Data
and Study Designs

View Safety Data See the full study designs
Dosage and
Administration
See the recommended dosing and
administration options for patients
on DUPIXENT.
Explore ADMINISTRATION Options